FDA Approves Betrixaban for the Prophylaxis of Venous Thromboembolism

June 27, 2017 – On June 23, 2017, the U.S. Food and Drug Administration (FDA) approved betrixaban for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Approval was based on data from the APEX study, a randomized, double-blind, multinational clinical trial … (leggi tutto)